Patents Assigned to Intermune, Inc.
  • METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM
    Publication number: 20140228310
    Abstract: Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system.
    Type: Application
    Filed: April 28, 2014
    Publication date: August 14, 2014
    Applicant: InterMune, Inc.
    Inventors: Lawrence M. Blatt, Scott D. Seiwert, Leonid D. Beigelman, Ramachandran Radhakrishnan, Karl Kossen, Vladimir Serebryany
  • METHOD FOR SYNTHESIZING PIRFENIDONE
    Publication number: 20140221660
    Abstract: A process for synthesizing pirfenidone from bromobenzene having less than about 0.15% by weight dibromobenze is disclosed. Also disclosed are processes of synthesizing pirfenidone without using ethyl acetate or n-butanol, and pirfenidone having controlled levels of ethyl acetate, n-butanol, di(5-methyl-2-pyridinone)benzenes, and other impurities having specified retention times. Also disclosed are formulated dosage forms including the disclosed pirfenidone.
    Type: Application
    Filed: April 8, 2014
    Publication date: August 7, 2014
    Applicant: INTERMUNE, INC.
    Inventors: Sabine M. Pyles, Michael Cyr, Ramachandran Radhakrishnan
  • ALTERING PHARMACOKINETICS OF PIRFENIDONE THERAPY
    Publication number: 20140221434
    Abstract: The invention relates to methods for reducing adverse events in patients receiving pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy.
    Type: Application
    Filed: April 7, 2014
    Publication date: August 7, 2014
    Applicant: INTERMUNE, INC.
    Inventors: Cynthia Y. Robinson, Jeffery S. Loutit, Michelle M. Freemer
  • Methods of administering pirfenidone therapy
    Patent number: 8778947
    Abstract: The disclosure relates to improved methods of administering pirfenidone therapy when ciprofloxacin is administered concomitantly.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: July 15, 2014
    Assignee: Intermune, Inc.
    Inventor: Williamson Z. Bradford
  • Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
    Patent number: 8753679
    Abstract: A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: June 17, 2014
    Assignee: Intermune, Inc.
    Inventors: Ramachandran Radhakrishnan, Ronald Vladyka, Kenneth Sultzbaugh
  • Pirfenidone therapy and inducers of cytochrome P450
    Patent number: 8754109
    Abstract: The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: June 17, 2014
    Assignee: Intermune, Inc.
    Inventors: Williamson Z. Bradford, Javier Szwarcberg
  • Method of modulating stress-activated protein kinase system
    Patent number: 8741936
    Abstract: Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system.
    Type: Grant
    Filed: June 20, 2012
    Date of Patent: June 3, 2014
    Assignee: Intermune, Inc.
    Inventors: Lawrence M. Blatt, Scott D. Seiwert, Leonid Beigelman, Ramachandran Radhakrishnan, Karl Kossen, Vladimir Serebryany
  • Pirfenidone Treatment for Patients with Atypical Liver Function
    Publication number: 20140073673
    Abstract: Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.
    Type: Application
    Filed: November 12, 2013
    Publication date: March 13, 2014
    Applicant: INTERMUNE, INC.
    Inventors: Williamson Z. Bradford, Javier Swarcberg
  • METHODS OF ADMINISTERING PIRFENIDONE THERAPY
    Publication number: 20140066484
    Abstract: The disclosure relates to improved methods of administering pirfenidone therapy when ciprofloxacin is administered concomitantly.
    Type: Application
    Filed: August 30, 2013
    Publication date: March 6, 2014
    Applicant: INTERMUNE, INC.
    Inventor: Williamson Z. Bradford
  • Pirfenidone therapy and inducers of cytochrome P450
    Patent number: 8648098
    Abstract: The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: February 11, 2014
    Assignee: Intermune, Inc.
    Inventors: Williamson Ziegler Bradford, Javier Szwarcberg
  • METHOD FOR SYNTHESIZING PIRFENIDONE
    Publication number: 20130345430
    Abstract: A process for synthesizing pirfenidone from bromobenzene having less than about 0.15% by weight dibromobenze is disclosed. Also disclosed are processes of synthesizing pirfenidone without using ethyl acetate or n-butanol, and pirfenidone having controlled levels of ethyl acetate, n-butanol, di(5-methyl-2-pyridinone)benzenes, and other impurities having specified retention times. Also disclosed are formulated dosage forms including the disclosed pirfenidone.
    Type: Application
    Filed: July 22, 2013
    Publication date: December 26, 2013
    Applicant: INTERMUNE, INC.
    Inventors: Sabine M. Pyles, Michael Cyr, Ramachandran Radhakrishnan
  • Pirfenidone treatment for patients with atypical liver function
    Patent number: 8609701
    Abstract: Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: December 17, 2013
    Assignee: Intermune, Inc.
    Inventors: Williamson Ziegler Bradford, Javier Szwarcberg
  • Pirfenidone treatment for patients with atypical liver function
    Patent number: 8592462
    Abstract: Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: November 26, 2013
    Assignee: Intermune, Inc.
    Inventors: Williamson Ziegler Bradford, Javier Szwarcberg
  • ALTERING PHARMACOKINETICS OF PIRFENIDONE THERAPY
    Publication number: 20130225639
    Abstract: The invention relates to methods for reducing adverse events in patients receiving pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy.
    Type: Application
    Filed: April 5, 2013
    Publication date: August 29, 2013
    Applicant: INTERMUNE, INC.
    Inventor: INTERMUNE, INC.
  • METHOD OF PROVIDING PIRFENIDONE THERAPY TO A PATIENT
    Publication number: 20130220871
    Abstract: The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme.
    Type: Application
    Filed: April 11, 2013
    Publication date: August 29, 2013
    Applicant: INTERMUNE, INC.
    Inventor: Intermune, Inc.
  • Method for synthesizing pirfenidone
    Patent number: 8519140
    Abstract: A process for synthesizing pirfenidone from bromobenzene having less than about 0.15% by weight dibromobenze is disclosed. Also disclosed are processes of synthesizing pirfenidone without using ethyl acetate or n-butanol, and pirfenidone having controlled levels of ethyl acetate, n-butanol, di(5-methyl-2-pyridinone)benzenes, and other impurities having specified retention times. Also disclosed are formulated dosage forms including the disclosed pirfenidone.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: August 27, 2013
    Assignee: Intermune, Inc.
    Inventors: Ramachandran Radhakrishnan, Michael Cyr, Sabine M. Pyles
  • Capsule Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients
    Publication number: 20130165484
    Abstract: A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need.
    Type: Application
    Filed: February 25, 2013
    Publication date: June 27, 2013
    Applicant: INTERMUNE, INC.
    Inventor: Intermune, Inc.
  • METHODS OF DIAGNOSING AND TREATING IDIOPATHIC PULMONARY FIBROSIS
    Publication number: 20130150426
    Abstract: Described herein are materials and methods for the diagnosis of idiopathic pulmonary fibrosis.
    Type: Application
    Filed: November 21, 2012
    Publication date: June 13, 2013
    Applicant: INTERMUNE, INC.
    Inventor: INTERMUNE, INC.
  • COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS
    Publication number: 20130102597
    Abstract: Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system.
    Type: Application
    Filed: October 15, 2012
    Publication date: April 25, 2013
    Applicant: INTERMUNE, INC.
    Inventor: INTERMUNE, INC.
  • Method of providing pirfenidone therapy to a patient
    Patent number: 8420674
    Abstract: The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme.
    Type: Grant
    Filed: July 7, 2010
    Date of Patent: April 16, 2013
    Assignee: Intermune, Inc.
    Inventor: Williamson Z. Bradford